查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2024年气道可逆疾病治疗全球市场报告
市场调查报告书
商品编码
1415691

2024年气道可逆疾病治疗全球市场报告

Reversible Airway Diseases Treatment Global Market Report 2024
出版日期: 按订单生产 | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，气道可逆疾病治疗市场规模强劲成长。从2023年的794.3亿美元增加到2024年的855.3亿美元，复合年增长率为7.7%。业绩期间的成长是由于气道可逆性疾病盛行率上升、人们对气道可逆性疾病的认识提高、获得医疗保健的机会增加以及可支配收入增加。

气道可逆疾病治疗市场规模预计在未来几年将强劲成长。到2028年，这一数字将以6.6%的年复合成长率（CAGR）增长至1,102.8亿美元。预测期内的成长是由于人口老化、慢性病盛行率上升、都市化和空气污染加剧以及医疗保健覆盖率扩大。预测期内的主要趋势包括数位健康技术的进步、新治疗方法的研发、早期疗育和预防以及吸入器技术。

慢性呼吸道疾病的盛行率不断上升被认为是在可预见的未来气道可逆疾病治疗市场扩大的关键驱动力。慢性呼吸系统疾病包括影响呼吸系统的多种疾病，呼吸系统由肺部、支气管、气管、喉、咽和鼻腔组成。慢性呼吸系统疾病的检测和治疗起着至关重要的作用，特别是在急性呼吸窘迫症候群等疾病的早期发现和诊断方面。及时介入和有效管理可降低这些疾病併发症和进展的风险。例如，根据瑞士民间社会组织非传染性疾病死亡联盟的资料，截至 2021 年 2 月，肺癌是全球癌症相关死亡的主要原因，新患者220 万，死亡人数达 180 万人。此外，根据《柳叶刀》2022年9月公布的资料，2021年新增呼吸道融合细胞病毒病例11,255例，比2020年报告的9,972例增加了11.4%。因此，慢性呼吸道疾病盛行率的上升预计将推动气道可逆疾病治疗市场的成长。

预计不断增长的医疗保健支出将成为未来几年气道可逆疾病治疗市场成长的主要动力。医疗保健支出包括特定医疗保健系统或经济体在特定时期内分配给医疗保健服务和相关活动的财政资源总额。卫生支出的成长趋势在治疗气道可逆性疾病方面尤其重要，因为它们推动了对研发、病患教育、先进药物的取得和最尖端科技开发的投资增加。因此，增加医疗支出将有助于改善受可逆性气道疾病影响的患者的管理和结果。例如，截至2022年11月，加拿大卫生组织加拿大健康资讯研究所（CIHI）的报告指出，2021年加拿大的医疗保健支出将达到3,280亿美元，随后在2022年增加至3,310亿美元。因此，急剧上升的医疗成本正在推动气道可逆疾病治疗市场的扩张。

2023年，北美是气道可逆疾病治疗市场中最大的地区。预计亚太地区将成为预测期内成长最快的地区。气道可逆疾病治疗报告涵盖的地区包括亚太地区、西欧、中欧和东欧、北美、南美和中东/非洲。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球市场驱动因素与抑制因素
    • 市场驱动因素
    • 市场抑制因素
  • 2018-2023 年全球市场规模表现与成长
  • 全球市场规模预测与成长，2023-2028、2033

第六章市场区隔

  • 全球气道可逆疾病治疗市场，依治疗、表现及预测细分，2018-2023、2023-2028、2033
  • 胸部X光检查
  • 电脑断层扫描 (CT) 扫描
  • 肺部治疗
  • 手术植入
  • 药品
  • 全球气道可逆疾病治疗市场，依疾病、表现及预测细分，2018-2023、2023-2028、2033
  • 气喘
  • 慢性支气管炎
  • 气肿
  • 囊肿纤维化
  • 细支气管炎
  • 其他的
  • 全球气道可逆疾病治疗市场，依最终用户细分、绩效和预测，2018-2023、2023-2028、2033
  • 医院
  • 专科诊所
  • 其他的

第 7 章 区域与国家分析

  • 全球气道可逆疾病治疗市场，按地区、绩效及预测，2018-2023、2023-2028、2033
  • 全球气道可逆疾病治疗市场，依国家、绩效及预测，2018-2023、2023-2028、2033

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争形势及公司概况

  • 气道可逆疾病治疗市场竞争形势
  • 气道可逆疾病治疗市场公司概况
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis AG

第三十一章 其他重大及创新企业

  • Sanofi SA
  • GlaxoSmithKline Plc
  • Medtronic plc
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Grifols SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dragerwerk AG & Co. KGaA
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

第32章竞争基准化分析

第 33 章. 竞争对手仪表板

第三十四章 重大併购

第35章 未来前景与可能性分析

第36章附录

简介目录
Product Code: r12290

“Reversible Airway Diseases Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for reversible airway diseases treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The reversible airway diseases treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment : Chest X Ray; Computed Tomography (CT) Scan; Lung Therapies; Surgery Transplant; Medications
  • 2) By Diseases: Asthma; Chronic Bronchitis; Emphysema; Cystic Fibrosis; Bronchiolitis; Other Diseases
  • 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $79.43 billion in 2023 to $85.53 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $110.28 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The increasing prevalence of chronic respiratory diseases is poised to be a significant driver of the reversible airway disease treatment market's expansion in the foreseeable future. Chronic respiratory diseases encompass a range of medical conditions affecting the respiratory system, comprising the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The testing and treatment of chronic respiratory diseases play a pivotal role in early detection and diagnosis, particularly for conditions like acute respiratory distress syndrome. Timely intervention and effective management reduce the risk of complications and the progression of these diseases. For example, as of February 2021, data from the NCD Alliance, a Switzerland-based civil society organization, reveals that lung cancer stands as the primary cause of cancer-related deaths on a global scale, accounting for 2.2 million new cases and 1.8 million fatalities. Furthermore, the data published by The Lancet in September 2022 indicates that there were 11,255 new cases of respiratory syncytial virus in 2021, marking an 11.4% increase from the 9,972 cases reported in 2020. Hence, the escalating incidence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

The restricted availability of vital inhaled therapies for individuals with COPD in low and middle-income countries (LMICs) is posing a hurdle to the growth of the reversible airway disease treatment market. Inhalation therapy is a medical approach that enables the direct delivery of medications into the airways via inhalation devices. However, in LMICs, there is a lack of access to and affordability of crucial inhaled therapies for individuals with COPD, which can limit their ability to receive effective treatment options. For example, as of October 2022, data from the Lancet Global Health indicated that only six out of 58 countries achieved the 80% availability target for short-acting beta-agonists (SABAs), and merely three out of 48 met the minimum requirement for inhaled corticosteroids (ICSs). Consequently, the inadequate accessibility of essential inhaled therapies for COPD patients in low- and middle-income countries (LMICs) is impeding the advancement of the reversible airway disease treatment market.

The prominent companies within the reversible airway disease treatment market are placing a significant emphasis on inhalation-based dosage forms for respiratory drug delivery to maintain their market presence. For instance, in June 2021, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Tiogiva, a Tiotropium Bromide Dry Powder Inhaler (DPI) in the United Kingdom. Tiogiva is a bioequivalent alternative to Boehringer Ingelheim's Spiriva Handihaler, designed for managing chronic obstructive pulmonary disease (COPD). COPD is a chronic condition characterized by lung inflammation, damage to lung tissue, and airway constriction. Glenmark Pharmaceuticals has plans to expand the product's availability throughout Western Europe, introducing it under various brand names such as Tiogiva in Ireland, Sweden, Finland, and Norway; Tavulus in Denmark, Spain, and the Netherlands; and Tiotropium Glenmark in Germany.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major players in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline Plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited .

North America was the largest region in the reversible airway diseases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Reversible Airway Diseases Treatment Market Size and Growth

  • 5.1. Global Reversible Airway Diseases Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Reversible Airway Diseases Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Reversible Airway Diseases Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Reversible Airway Diseases Treatment Market Segmentation

  • 6.1. Global Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chest X Ray
  • Computed Tomography (CT) Scan
  • Lung Therapies
  • Surgery Transplant
  • Medications
  • 6.2. Global Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Asthma
  • Chronic Bronchitis
  • Emphysema
  • Cystic Fibrosis
  • Bronchiolitis
  • Other Diseases
  • 6.3. Global Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

  • 7.1. Global Reversible Airway Diseases Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Reversible Airway Diseases Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Reversible Airway Diseases Treatment Market

  • 8.1. Asia-Pacific Reversible Airway Diseases Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Reversible Airway Diseases Treatment Market

  • 9.1. China Reversible Airway Diseases Treatment Market Overview
  • 9.2. China Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Reversible Airway Diseases Treatment Market

  • 10.1. India Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Reversible Airway Diseases Treatment Market

  • 11.1. Japan Reversible Airway Diseases Treatment Market Overview
  • 11.2. Japan Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Reversible Airway Diseases Treatment Market

  • 12.1. Australia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Reversible Airway Diseases Treatment Market

  • 13.1. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Reversible Airway Diseases Treatment Market

  • 14.1. South Korea Reversible Airway Diseases Treatment Market Overview
  • 14.2. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Reversible Airway Diseases Treatment Market

  • 15.1. Western Europe Reversible Airway Diseases Treatment Market Overview
  • 15.2. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Reversible Airway Diseases Treatment Market

  • 16.1. UK Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Reversible Airway Diseases Treatment Market

  • 17.1. Germany Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Reversible Airway Diseases Treatment Market

  • 18.1. France Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Reversible Airway Diseases Treatment Market

  • 19.1. Italy Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Reversible Airway Diseases Treatment Market

  • 20.1. Spain Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Reversible Airway Diseases Treatment Market

  • 21.1. Eastern Europe Reversible Airway Diseases Treatment Market Overview
  • 21.2. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Reversible Airway Diseases Treatment Market

  • 22.1. Russia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Reversible Airway Diseases Treatment Market

  • 23.1. North America Reversible Airway Diseases Treatment Market Overview
  • 23.2. North America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Reversible Airway Diseases Treatment Market

  • 24.1. USA Reversible Airway Diseases Treatment Market Overview
  • 24.2. USA Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Reversible Airway Diseases Treatment Market

  • 25.1. Canada Reversible Airway Diseases Treatment Market Overview
  • 25.2. Canada Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Reversible Airway Diseases Treatment Market

  • 26.1. South America Reversible Airway Diseases Treatment Market Overview
  • 26.2. South America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Reversible Airway Diseases Treatment Market

  • 27.1. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Reversible Airway Diseases Treatment Market

  • 28.1. Middle East Reversible Airway Diseases Treatment Market Overview
  • 28.2. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Reversible Airway Diseases Treatment Market

  • 29.1. Africa Reversible Airway Diseases Treatment Market Overview
  • 29.2. Africa Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Reversible Airway Diseases Treatment Market Competitive Landscape
  • 30.2. Reversible Airway Diseases Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. GlaxoSmithKline Plc
  • 31.3. Medtronic plc
  • 31.4. Eli Lilly and Company
  • 31.5. Gilead Sciences Inc.
  • 31.6. Amgen Inc.
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Grifols SA
  • 31.11. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Dragerwerk AG & Co. KGaA
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking

33. Global Reversible Airway Diseases Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market Future Outlook and Potential Analysis

  • 35.1 Reversible Airway Diseases Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Reversible Airway Diseases Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Reversible Airway Diseases Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer